ASCO 2015 Highlights

Single-Agent Clofarabine versus Standard Daunorubicin/Cytarabine Regimen As Induction and Consolidation Therapy in Older Adults with Newly Diagnosed AML: Results of the Phase 3 E2906 Trial

ASH 2015 – Leukemia, ASH Highlights

Conference Correspondent

Clofarabine-Based Consolidation in Younger Adults with AML in First Remission: Results of the Randomized ALFA-0702/CLARA Study

ASH 2015 – Leukemia, ASH Highlights

Conference Correspondent

Intermediate-Dose Cytarabine/Mitoxantrone versus Standard-Dose Cytarabine/Daunorubicin Induction Therapy in AML Patients >60 Years: Results from the SAL 60+ Trial

ASH 2015 – Leukemia, ASH Highlights

Conference Correspondent

Addition of Rituximab to Chemotherapy in Adult Patients with CD20-Positive, Ph-Negative, B-Cell Precursor ALL: Results of the Randomized Graall-R 2005 Study

ASH 2015 – Leukemia, ASH Highlights

Conference Correspondent

Blinatumomab Treatment in Adult Patients with Relapsed/Refractory Ph+ ALL: Results from the Phase 2 ALCANTARA Trial

ASH 2015 – Leukemia, ASH Highlights

Conference Correspondent

Long-Term Outcomes of Blinatumomab Treatment in Patients with MRD-Positive ALL

ASH 2015 – Leukemia, ASH Highlights

Conference Correspondent

Imatinib versus Dasatinib in Newly Diagnosed Chronic-Phase CML: Quality-of-Life Assessment in the NCRI SPIRIT2 Study

ASH 2015 – Leukemia, ASH Highlights

Conference Correspondent

Blinatumomab Treatment in Adult Patients with Relapsed/Refractory B-Precursor ALL Post-Allogeneic Hematopoietic Stem-Cell Transplantation

ASH 2015 – Leukemia, ASH Highlights

Conference Correspondent

Dose-Optimized Nilotinib in Patients with Newly Diagnosed CML-CP: Final Results from ENESTxtnd Study

ASH 2015 – Leukemia, ASH Highlights

Conference Correspondent

Effect of Nilotinib Treatment Duration on Treatment-Free Remission in CP-CML Patients Previously Treated with Imatinib: Interim Results of the ENESTPath Phase 3 Trial

ASH 2015 – Leukemia, ASH Highlights

Conference Correspondent

Page 177 of 330